| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
29,063 |
22,641 |
$947K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,407 |
7,558 |
$526K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,992 |
2,674 |
$145K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
338 |
274 |
$81K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,561 |
7,137 |
$64K |
| 80053 |
Comprehensive metabolic panel |
6,002 |
4,458 |
$50K |
| 87400 |
|
10,877 |
4,292 |
$48K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
445 |
404 |
$20K |
| 81003 |
|
9,394 |
7,098 |
$19K |
| 87430 |
|
1,335 |
982 |
$16K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,341 |
256 |
$14K |
| 87077 |
|
1,634 |
1,199 |
$11K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
41 |
35 |
$6K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
362 |
72 |
$6K |
| 71046 |
Radiologic examination, chest; 2 views |
621 |
453 |
$5K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
26 |
12 |
$3K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
71 |
66 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
309 |
235 |
$3K |
| 0001A |
|
47 |
47 |
$2K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
50 |
12 |
$1K |
| 83735 |
|
179 |
141 |
$994.14 |
| 81025 |
|
350 |
264 |
$898.86 |
| 87449 |
|
96 |
55 |
$882.20 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
50 |
44 |
$804.46 |
| 0002A |
|
25 |
20 |
$800.00 |
| 71045 |
Radiologic examination, chest; single view |
120 |
104 |
$793.34 |
| 81001 |
|
135 |
116 |
$411.38 |
| 83690 |
|
49 |
36 |
$258.56 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
31 |
24 |
$255.45 |
| 80306 |
|
14 |
12 |
$147.52 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
18 |
12 |
$98.64 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
16 |
15 |
$97.50 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
57 |
45 |
$48.24 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
21 |
16 |
$39.06 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
24 |
19 |
$0.03 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
29 |
27 |
$0.00 |
| G0379 |
Direct admission of patient for hospital observation care |
25 |
12 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
59 |
51 |
$0.00 |
| 91300 |
|
118 |
80 |
$0.00 |